Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)
Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST
Sponsor: Bayer
Listed as NCT02638766, this PHASE2 trial focuses on Gastrointestinal Stromal Tumors and remains completed. Sponsored by Bayer, it has been updated 8 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jan 2021 — Apr 2023 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jan 2020 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Grupo Espanol de Investigacion en Sarcomas
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barakaldo, Spain , Barcelona, Spain , Bordeaux, France , Lyon, France , Madrid, Spain , Milan, Italy , Napoli, Italy , Roma, Italy , San Cristóbal de La Laguna, Spain , Seville, Spain and 4 more locations